advertisement

---

Expert Opinion on Therapeutic Patents 16

Showing records 1 to 16 | Display all abstracts in Expert Opinion on Therapeutic Patents

82353 Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)
Nocentini A
Expert Opinion on Therapeutic Patents 2019; 29: 805-815

---

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Guglielmi P
Expert Opinion on Therapeutic Patents 2019; 29: 769-780

---

82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Bonardi A
Expert Opinion on Therapeutic Patents 2019; 29: 753-759

---

82395 Diagnostic markers for glaucoma: a patent and literature review (2013-2019)
Bua S
Expert Opinion on Therapeutic Patents 2019; 29: 829-839

---

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792

---

82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Angeli A
Expert Opinion on Therapeutic Patents 2019; 29: 793-803

---

82535 Rho-kinase inhibitors in the management of glaucoma
Berrino E
Expert Opinion on Therapeutic Patents 2019; 29: 817-827

---

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792

---

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Carradori S
Expert Opinion on Therapeutic Patents 2019; 29: 769-780

---

82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 793-803

---

82535 Rho-kinase inhibitors in the management of glaucoma
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 817-827

---

82353 Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 805-815

---

82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 753-759

---

82395 Diagnostic markers for glaucoma: a patent and literature review (2013-2019)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 829-839

---

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792

---

82163 Novel therapies for glaucoma: a patent review (2013-2019)
Campestre C; Poce G
Expert Opinion on Therapeutic Patents 2019; 29: 769-780

---